- Open Access
Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway
© Wang et al.; licensee BioMed Central Ltd. 2013
- Received: 2 August 2013
- Accepted: 20 December 2013
- Published: 27 December 2013
The miR-9 family microRNAs have been identified as a tumor suppressor miRNA in cancers. We postulated that miR-9-1, miR-9-2 and miR-9-3 might be inactivated by DNA hypermethylation in chronic lymphocytic leukemia (CLL).
Methylation of miR-9-1, miR-9-2 and miR-9-3 was studied in eight normal controls including normal bone marrow, buffy coat, and CD19-sorted peripheral blood B-cells from healthy individuals, seven CLL cell lines, and seventy-eight diagnostic CLL samples by methylation-specific polymerase chain reaction.
The promoters of miR-9-3 and miR-9-1 were both unmethylated in normal controls, but methylated in five (71.4%) and one of seven CLL cell lines respectively. However, miR-9-2 promoter was methylated in normal controls including CD19 + ve B-cells, hence suggestive of a tissue-specific but not tumor-specific methylation, and thus not further studied. Different MSP statuses of miR-9-3, including complete methylation, partial methylation, and complete unmethylation, were verified by quantitative bisulfite methylation analysis. 5-Aza-2′-deoxycytidine treatment resulted in miR-9-3 promoter demethylation and re-expression of pri-miR-9-3 in I83-E95 and WAC3CD5+ cells, which were homozygously methylated for miR-9-3. Moreover, overexpression of miR-9 led to suppressed cell proliferation and enhanced apoptosis together with downregulation of NFκB1 in I83-E95 cells, supporting a tumor suppressor role of miR-9-3 in CLL. In primary CLL samples, miR-9-3 was detected in 17% and miR-9-1 methylation in none of the patients at diagnosis. Moreover, miR-9-3 methylation was associated with advanced Rai stage (≥ stage 2) (P = 0.04).
Of the miR-9 family, miR-9-3 is a tumor suppressor miRNA relatively frequently methylated, and hence silenced in CLL; whereas miR-9-1 methylation is rare in CLL. The role of miR-9-3 methylation in the constitutive activation of NFκB signaling pathway in CLL warrants further study.
- Tumor suppressor
- DNA methylation
- Chronic lymphocytic leukemia
DNA methylation refers to the chemical modification of the cytosine ring in a CpG dinucleotide by the addition of a methyl group (-CH3) to the number 5 carbon of the cytosine pyrimidine ring in the CpG dinucleotide, resulting in the formation of 5-methylcytosine . Global DNA hypomethylation, but aberrant, gene-specific DNA hypermethylation of the promoter-associated CpG islands of tumor suppressor genes (TSGs), is a hallmark of many human cancers [2, 3]. Methylation of multiple TSGs has involved in the dysregulation of signaling pathways in leukemia, lymphoma and myeloma, including cell cycle (CDKN2A/B), apoptosis (DAPK1/CDKN2A/APAF1), JAK/STAT signaling and WNT signaling; thereby indicating the importance of TSGs methylation in the pathogenesis of hematological cancers [4–6]. Of note, the DNA hypermethylation in TSGs, such as DAPK1, ID4, SFRP1, TWIST2 and ZAP70, has been identified to play a role in the pathogenesis or prognosis of chronic lymphocytic leukemia (CLL) [7–11].
Mature microRNA (miRNAs) are endogenous, single-stranded, non-protein-coding small RNAs measuring 19 to 25 nucleotides (nts), which suppress the expression of proteins that they target [12, 13]. In carcinogenesis, miRNAs can be categorized into either oncogenic (oncomirs) or tumor suppressor miRNAs [14, 15]. Recently, tumor suppressor miRNAs have shown to be silenced by aberrant DNA hypermethylation in cancers [1, 16, 17]. Furthermore, previous studies also identified methylation of some tumor suppressor miRNAs, including miR-203, miR-124-1, miR-181a/b, miR-107 and miR-424, to be involved in CLL leukemogenesis .
In humans, there are three independent miR-9 genes (miR-9-1 on chromosome 1; miR-9-2 on chromosome 5 and miR-9-3 on chromosome 15), with identical mature miR-9 sequence. In cancers, miR-9 could be either oncomir or tumor suppressor miRNA, depending on the type of cancers or tissues [19, 20]. For instance, overexpression of miR-9 has been shown to enhance metastasis or invasion in breast cancer cells or glioblastoma, identifying its oncogenic role [21–23]. Conversely, miR-9 has been shown to target and repress NFκB1 translation in ovarian tumor cells by binding to the 3′ untranslated region (3′ UTR) of the NFκB1 mRNA, leading to inhibition of cell proliferation; hence demonstrating a tumor suppressor function .
In this report, we studied methylation of miR-9-3, in addition to miR-9-1 and miR-9-2 in a representative cohort of CLL to define its pathogenetic role.
Bone marrow samples were obtained from 78 CLL patients at diagnosis. The diagnosis of CLL was made according to the WHO Classification, based on classical morphology, low level of expression of light-chain-restricted surface immunoglobulin, and concomitant expression of CD5 and CD23 as demonstrated by flow cytometry [25, 26]. Of the 78 CLL patients, there were 51 male (65.4%) and 27 female (34.6%) patients at a median age of 65 years (range: 37–91 years). The median presenting lymphocyte count was 18 × 109/L (range: 10–540 × 109/L). Apart from 8 patients with insufficient Rai stage data, there were 42 (60.0%) limited Rai stage (<stage II) and 28 (40.0%) advanced Rai stage (≥stage II) patients. Among the 53 patients with cytogenetic information, 13 (24.5%) carried high/intermediate-risk cytogenetic aberrations [del(17p), N = 2; del(11q), N = 2; trisomy 12, N = 9] and 40 (75.5%) carried low/standard-risk cytogenetic alterations [del(13q), N = 12; normal karyotype, N = 21; other karyotypic changes, N = 7]. The median overall survival (OS) of this cohort was 69 months. The median OS of those with advanced Rai stage and limited Rai stage were 49 and 111 months respectively (P = 0.006). Furthermore, the median OS for those with or without high/intermediate-risk karyotype were 28 months and 111 months respectively (P = 0.003). Samples were obtained with written informed consent, and the study was approved by the Institutional Review Board of Queen Mary Hospital and in accordance with the Declaration of Helsinki.
Cell lines and culture
The human CLL cell lines CLL-AAT and MEC1 were purchased from American Type Culture Collection (Manassas, USA) and Deutsche Sammlung von Mikroorganismen und Zellkulturen Deutsche GmbH (DMSZ) (Braunschweig, Germany) respectively. MEC2, I83-E95 and WAC3CD5+ were kindly provided by Dr John C. Byrd, Department of Medicine, Ohio State University [27, 28]. HG3 and 232B4 were kind gifts from Prof. Anders Rosén, Department of Clinical & Experimental Medicine, Linköping University [28, 29]. Cell cultures were maintained in RPMI medium 1640, supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO2 at 37°C.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from seventy-eight bone marrow samples of CLL at diagnosis, seven cell lines and eight normal controls (CD19 sorted peripheral blood B cells from healthy donors, N = 3; peripheral blood buffy coats from healthy donors, N = 2; and bone marrow buffy coats from healthy donors, N = 3) by the QIAamp DNA Blood Mini Kit (QIAGEN, Germany). The MSP for aberrant gene promoter methylation was performed as described in detail previously . Each sample was amplified with two sets of primers, one set for methylated DNA (methylated MSP) and one set for unmethylated DNA (unmethylated MSP). Treatment of DNA with bisulfite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with the EpiTect Bisulfite Kit kit (QIAGEN, Germany). Details of primers and conditions for MSP of miR-9-1, miR-9-2 and miR-9-3 were given in Additional file 1: Table S1.
Quantitative bisulfite pyrosequencing
DNA was treated with bisulfite and used as template. Primers for pyrosequencing were used to amplify the promoter region, which was overlapped with the amplicon of MSP. Primers were designed using PSQ Assay Design software (Biotage). Forward primer: 5′-GAAGGGGGTTGGGATTTGA-3′; Reverse primer: 5′-ATTTCTCCCCTACTCCCC-3′; condition: 2mM/61°C/50X. A stretch of DNA with 9 adjacent CpG dinucleotides was pyrosequenced by sequencing primer: 5′-ATGGGAGTTTGTGAT-3′.
5-Aza-2′-deoxycytidine (5-AzadC) treatment
I83-E95 and WAC3CD5+ cells at log-phase were cultured in six-well plates at a density of 1 × 106 cells/ml, with 0.5 μM of 5-AzadC (Sigma-Aldrich, St. Louis, MO, USA) for 5 days respectively, as described . Fresh 5-AzadC was replaced every 24 hours. I83-E95 and WAC3CD5+ cells on day 0 and day 5 of 5-AzadC treatment were harvested respectively.
Quantification of pri-miR-9-3 and miR-9
According to the manufacturer’s instructions, total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). For quantification of pri-miR-9-3, miRNA was reversely transcribed by the QuantiTect Reverse Transcription Kit (QIAGEN, Valencia, CA), and quantified using the TaqMan Pri-miRNA Assay (ABI, Foster City, CA). GAPDH was used as reference for data analysis using the 2-∆∆CT method . Moreover, miR-9 was quantified by the TaqMan MicroRNA RT Kit, and TaqMan MicroRNA Assay Kit. RNU48 was chosen as reference using the 2-∆∆CT method .
Overexpression of miR-9 precursor
According to the manufacturers’ instructions, precursor miR-9 mimic (final concentration 100 nM) (Ambion, Austin, TX, USA) was transfected into 1 × 106 I83-E95 cells and WAC3CD5+ cells respectively, using X-tremeGENE siRNA Transfection Reagent (Roche, Basel, Switzerland), as described . Non-targeting oligonucleotide mimic was used as the negative control.
Cell proliferation, viability analyses
The MTT method was used to determine cellular proliferation . Cells were seeded in a 96-well microtitre plate at 2.5 × 104/well in 100 μl of medium. At the assay test time point 48 hours after transfection, 10 μl of 5 mg/ml MTT reagent was added to each well and incubated for 4 hours. Then each well was added with 100 μl dimethyl sulfoxide (DMSO), followed by the measurement of absorbance at 550 nm with reference to 650 nm. Cellular viability assay was performed by the Trypan blue dye exclusion assay under microscope. Dead cells (%) = (total number of dead cells per microscopic field/ total number of cells per microscopic field) × 100. Five random microscopic fields were counted in each sample.
Cellular apoptosis analysis
Cell apoptosis was assessed by flow cytometry using FITC Annexin V and PI staining as described previously . FITC Annexin V Apoptosis Detection Kit I (BD-Pharmingen) was used here. 1 × 106 I83-E95 or WAC3CD5+ cells were washed with cold PBS and resuspended in 100 μl binding buffer with 5 ul of Annexin V and 5 ul PI, and then incubated for 15 minutes at room temperature in the dark. After adding 400 μl binding buffer to each tube, samples were analyzed by flow cytometry (BD FACS Canto II). FITC Annexin V positive, PI negative or FITC Annexin V positive, PI positive cells were counted as apoptosis cells.
Western blot for NFκB1
After 48 hours transfection, I83-E95 cells were harvested and lysed in RIPA buffer (50 mM Tris- HCl, pH 7.4, 150 mM NaCl, 0.2% SDS, 1% Triton X-100, 2 mM EDTA). Protein lysates were separated on 10% SDS-PAGE and blotting were performed on a 0.2 μm nitrocellulose membrane (Bio-Rad, Hercules, CA). The membranes were incubated with NFκB1 (1:1000; Santa Cruz, CA) or anti-actin (1:5000; Sigma-Aldrich, USA) primary antibody at 4°C overnight. Then membranes were washed and incubated with anti-rabbit horseradish peroxidase conjugate secondary antibody at room temperature for 1 hour. Protein signals were detected by ECL plus Western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK) and exposed to X-ray film.
In CLL, the association of miR-9-3 methylation status with continuous variables (such as mean age, mean lymphocyte counts, diagnostic hemoglobin or platelet counts) and categorical variables (gender, Rai stage or high-risk karyotypes) were analyzed by student’s t-test and chi-square test (or Fisher’s exact test) respectively. OS is assessed from the date of diagnosis to the date of last follow-up or death. OS of patients with limited Rai stage (stages 0, I and II) was compared with those with advanced Rai stage (stages III and IV). Furthermore, OS of patients with high-risk karyotypes [del(17p), del(11q) or trisomy 12] was compared to those with standard-risk karyotypes [del(13q), normal karyotype or other karyotypic changes]. The mean values of MTT assay, Trypan blue exclusion assay, FITC Annexin V and PI staining apoptosis analysis in I83-E95 or WAC3CD5+ cells transfected with precursor miR-9 mimic were compared to those transfected with the scrambled oligo by student’s t-test. Survival was plotted by the Kaplan–Meier method and compared by the log-rank test. All P values were two-sided.
CLL cell lines
Primary samples at diagnosis
5-AzadC treatment of I83-E95 and WAC3CD5+ cells
Effect of miR-9 overexpression in I83-E95 cells and WAC3CD5+ cells
Despite the retrospective nature, this cohort of patients had previously been shown to be typical of CLL, in that patients pursued an indolent course with prolonged survival, which was adversely impacted by advanced Rai stage and high-risk karyotypes.
Firstly, miR-9-3 and miR-9-1 methylation in CLL cell lines was tumor-specific as evidenced by the absence of methylation in normal peripheral blood buffy coat and CD19-sorted B-cells, and normal bone marrow cells. By contrast, miR-9-2 methylation appeared to occur both in normal CD19 + ve B-cells and CLL B-cells, and hence this pattern of methylation is tissue-specific but not tumor-specific . Similarly, miRNAs such as miR-127 and miR-373 have been shown hypermethylated in both normal and tumor cells, and hence represent tissue-specific but not tumor-specific miRNA methylation . On the other hand, a recent study of miRNAs deregulated by either gene hypo- or hyper-methylation in CLL showed methylation of miR-9-2 in CLL . This disparity might be accounted by the use of quantitative MassARRAY in their study, in which aberrant methylation of miR-9-2 was defined as a certain level of methylation above that occurring in normal controls. However, as Chinese have a much lower incidence of CLL, whether miR-9-2 methylation in Caucasian patients arose from a primary biological difference between the Asian and Western could not be excluded [38, 39].
Furthermore, upon the 5-AzadC treatment of I83-E95 and WAC3CD5+ cells, both of which were homozygously methylated for miR-9-3, emergence of U-MSP signal, and thus demethylation of miR-9-3 promoter, was correlated with pri-miR-9-3 re-expression. Therefore, miR-9-3 methylation is frequent in CLL cell lines, leading to the reversible miRNA silencing.
Moreover, tumor suppressor activity of miR-9-3 was demonstrated in CLL. We showed that restoration of miR-9 in I83-E95 cells harboring complete methylation of miR-9-3 led to reduced cellular proliferation and enhanced apoptosis. In addition, overexpression of miR-9 led to downregulation of NFκB1 (P105/P50), consistent with previous data that NFκB1 was a direct target of miR-9 by translational repression in ovarian cancer cells . On the other hand, while the tumor suppressor role of miR-9, due to epigenetically downregulation, has been reported in some cancers [19, 40–43]. miR-9 has also been implicated as an oncomir in other cancers. For example, in breast cancer cells, as a metastasis-promoting miRNA, miR-9 led to enhanced cell motility and hence invasiveness by targeting E-cadherin . In glioblastoma cells, overexpression of miR-9/9* could inhibit the expression of the tumor suppressor gene CAMTA1, leading to enhanced cell survival, implying that it might be an oncomir .
Interesting, we noted the significant association of miR-9-3 methylation with advanced Rai stage (≥ stage 2) in CLL patients, which is a poor risk factor for survival. Similarly, miR-9-3 methylation has been shown to be associated with metastatic recurrence in renal cell carcinoma , in addition to shorter disease-free and overall survivals in squamous cell lung cancer . However, apart from Rai stage, there was no association between the miR-9-3 methylation and other clinical parameters including age, gender, diagnostic hemoglobin, lymphocyte counts, high-risk karyotypic aberrations or survival. Given the small number of samples in our cohort, the possible role of miR-9-3 as a prognostic marker by impacting on survival requires validation in a larger scale study.
Constitutive activation of NFκB have played roles in carcinogenesis, including stimulating cell proliferation, inhibiting cell apoptosis and increasing tumor metastasis . Upon canonical NFκB activation by cytokines such as IL-1, IL-2 or TNFα, NFκB (a dimer comprising P50:P65) is released from the NFκB-IκBα complex, allowing nuclear translocation of NFκB and signaling activation [45, 46]. NFκB1 gene encodes 2 functional proteins, the cytoplasmic precursor P105 and the corresponding processed product P50. In HEK-293 cells and ovarian cancer ES-2 cells, NFκB1 has been shown to be a direct target of miR-9 by luciferase assay [24, 47]. Moreover, miR-9 overexpression suppressed tumor cell proliferation in association with repression of NFκB pathway, thereby confirming the tumor suppressive role of miR-9 via the regulation of NFκB signaling in ovarian cancer . Similarly, constitutive activation of NFκB activity has been demonstrated in CLL cells, conferring survival benefit through induction of a multitude of anti-apoptotic proteins including X-linked inhibitor of apoptosis protein (XIAP), FLICE-like inhibitory protein (FLIP) and members of the BCL2 family (BCL-XL and A1/BFL1) [48, 49]. In our study, we also showed that miR-9 overexpression in I83-E95 cells resulted in downregulation of NFκB1 (P105/P50) protein. Therefore, miR-9-3 methylation may account for constitutive upregulation of NFκB1, and hence constitutive NFκB activation in CLL patients.
Taken together, our results revealed that miR-9-3 was a tumor suppressor miRNA frequently methylated in CLL. miR-9-3 was a tumor suppressor miRNA hypermethylated in CLL, which was associated with down-regulation of NFκB1 protein, and hence might contribute to constitutive activation of NFκB signaling pathway in CLL.
We would like to thank Dr John Byrd, Department of Medicine, Ohio State University, USA for the CLL cell lines (MEC2, WAC3CD5+ and I83-E95) and Prof. Anders Rosén, Department of Clinical & Experimental Medicine, Linköping University for the CLL cell lines (HG3 and 232B4).
- Esteller M: Epigenetics in cancer. N Engl J Med. 2008, 358: 1148-1159. 10.1056/NEJMra072067View ArticlePubMedGoogle Scholar
- Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol. 2002, 20: 167-176. 10.1002/hon.694View ArticlePubMedGoogle Scholar
- Jones PA, Baylin SB: The epigenomics of cancer. Cell. 2007, 128: 683-692. 10.1016/j.cell.2007.01.029PubMed CentralView ArticlePubMedGoogle Scholar
- Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen TD, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995, 55: 4531-4535.PubMedGoogle Scholar
- Chim CS, Pang R, Fung TK, Choi CL, Liang R: Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 2007, 21: 2527-2536. 10.1038/sj.leu.2404939View ArticlePubMedGoogle Scholar
- Chim CS, Fung TK, Wong KF, Lau J, Liang R: Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J Hum Genet. 2006, 51: 832-838. 10.1007/s10038-006-0029-xView ArticlePubMedGoogle Scholar
- Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen S-S, Hackanson B, Grever MR, Lucas DM, Matkovic JJ: Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. Cell. 2007, 129: 879-890. 10.1016/j.cell.2007.03.043View ArticlePubMedGoogle Scholar
- Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F: Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011, 117: 862-871. 10.1182/blood-2010-05-284638PubMed CentralView ArticlePubMedGoogle Scholar
- Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C: CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 2006, 66: 653-658. 10.1158/0008-5472.CAN-05-3712View ArticlePubMedGoogle Scholar
- Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC: TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005, 23: 3877-3885. 10.1200/JCO.2005.02.196View ArticlePubMedGoogle Scholar
- Chantepie SP, Vaur D, Grunau C, Salaun V, Briand M, Parienti JJ, Heutte N, Cheze S, Roussel M, Gauduchon P: ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk Res. 2010, 34: 800-808. 10.1016/j.leukres.2009.10.018View ArticlePubMedGoogle Scholar
- Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136: 215-233. 10.1016/j.cell.2009.01.002PubMed CentralView ArticlePubMedGoogle Scholar
- Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005, 353: 1768-1771. 10.1056/NEJMp058190View ArticlePubMedGoogle Scholar
- Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302: 1-12. 10.1016/j.ydbio.2006.08.028View ArticlePubMedGoogle Scholar
- Wong KY, Huang X, Chim CS: DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012, 33: 1629-1638. 10.1093/carcin/bgs212View ArticlePubMedGoogle Scholar
- Yim RLH, Kwong YL, Wong KY, Chim CS: DNA methylation of tumor suppressive miRNAs in non-Hodgkin’s lymphomas. Front Genet. 2012, 3: 223-View ArticleGoogle Scholar
- Wang LQ, Liang R, Chim CS: Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Expert Rev Mol Diagn. 2012, 12: 755-765. 10.1586/erm.12.64View ArticlePubMedGoogle Scholar
- Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL: Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics. 2011, 6: 1189-1197. 10.4161/epi.6.10.16535PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, Zheng L, Tong Q: microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther. 2012, 11: 1454-1466. 10.1158/1535-7163.MCT-12-0001View ArticlePubMedGoogle Scholar
- Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010, 12: 247-256.PubMed CentralPubMedGoogle Scholar
- Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O: MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009, 19: 375-383. 10.1111/j.1750-3639.2008.00184.xPubMed CentralView ArticlePubMedGoogle Scholar
- Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP: CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J. 2011, 30: 4309-4322. 10.1038/emboj.2011.301PubMed CentralView ArticlePubMedGoogle Scholar
- Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-κB1. FEBS J. 2009, 276: 5537-5546. 10.1111/j.1742-4658.2009.07237.xView ArticlePubMedGoogle Scholar
- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008, 111: 5446-5456. 10.1182/blood-2007-06-093906PubMed CentralView ArticlePubMedGoogle Scholar
- Jaffe ES: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 2001, Lyon: LARC PressGoogle Scholar
- Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K: MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999, 23: 127-136. 10.1016/S0145-2126(98)00154-4View ArticlePubMedGoogle Scholar
- Wendel-Hansen V, Sällström J, De Campos-Lima P, Kjellström G, Sandlund A, Siegbahn A, Carlsson M, Nilsson K, Rosen A: Epstein-Barr virus (EBV) can immortalize B-cll cells activated by cytokines. Leukemia. 1994, 8: 476-484.PubMedGoogle Scholar
- Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L: Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncol Immunol. 2012, 1: 18-27.Google Scholar
- Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821PubMed CentralView ArticlePubMedGoogle Scholar
- Wong KY, Yim RLH, So CC, Jin DY, Liang R, Chim CS: Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood. 2011, 118: 5901-5904. 10.1182/blood-2011-06-361022View ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD:Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2ΔΔCT Method.Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262View ArticlePubMedGoogle Scholar
- Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS: Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol. 2011, 154: 569-578. 10.1111/j.1365-2141.2011.08782.xView ArticlePubMedGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4View ArticlePubMedGoogle Scholar
- van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP: A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry. 1996, 24: 131-139. 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-MView ArticlePubMedGoogle Scholar
- Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Gitt A: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67: 1424-1429. 10.1158/0008-5472.CAN-06-4218View ArticlePubMedGoogle Scholar
- Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch CP, Herpel E: Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia. Cancer Res. 2012, 72: 3775-3785. 10.1158/0008-5472.CAN-12-0803View ArticlePubMedGoogle Scholar
- Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R: Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol. 2006, 59: 921-926. 10.1136/jcp.2005.035089PubMed CentralView ArticlePubMedGoogle Scholar
- Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007, 139: 809-819. 10.1111/j.1365-2141.2007.06856.xView ArticlePubMedGoogle Scholar
- Hildebrandt M, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood C, Wu X: Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010, 29: 5724-5728. 10.1038/onc.2010.305View ArticlePubMedGoogle Scholar
- Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A: Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers. Clin Cancer Res. 2012, 18: 1619-1629. 10.1158/1078-0432.CCR-11-2450View ArticlePubMedGoogle Scholar
- Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008, 105: 13556-13561. 10.1073/pnas.0803055105PubMed CentralView ArticlePubMedGoogle Scholar
- Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009, 125: 2737-2743. 10.1002/ijc.24638View ArticlePubMedGoogle Scholar
- Karin M, Cao Y, Greten FR, Li Z-W: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780View ArticlePubMedGoogle Scholar
- Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-α-Induced Apoptosis by NF-κB. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787View ArticlePubMedGoogle Scholar
- Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001, 107: 7-12. 10.1172/JCI11830PubMed CentralView ArticlePubMedGoogle Scholar
- Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M: Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A. 2009, 106: 5282-5287. 10.1073/pnas.0810909106PubMed CentralView ArticlePubMedGoogle Scholar
- Furman RR, Asgary Z, Mascarenhas JO, Liou H-C, Schattner EJ: Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells. J Immunol. 2000, 164: 2200-2206.View ArticlePubMedGoogle Scholar
- Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A: A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004, 18: 1391-1400. 10.1038/sj.leu.2403398View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.